SCEPTRE MEDICAL DEVICES PRIVATE LIMITED
21 Central Market, Ashok Vihar, Delhi, India -110052
CIN: U33100DL2002PTC113888
Email: yogesh_m72@yahoo.com Telephone: 9811093036

NOTICE

Notice is hereby given that the 23rd (Twenty Third) Annual General Meeting of the Members of Sceptre Medical Devices Private Limited will be held on Tuesday, the 30th day of September 2025 at 11:30 A.M. at the registered office of the Company situated at 21 Central Market, Ashok Vihar, Delhi, India -110052 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended 31st March, 2025 and the reports of the Board of Directors and Auditors thereon.

2. **Regularization of Additional Director, Mr. Sukesh Arora (DIN: 10682240) as Director of the company.**
   To consider and, if thought fit, to pass with or without modifications, the following resolution as Ordinary Resolution:

   "RESOLVED THAT pursuant to provisions of Section 161 and all other applicable provisions, of the Companies Act, 2013 and Companies (Appointment and Qualification of Directors) Rules, 2014, including any enactment, re-enactment or modifications thereof, **Mr. Sukesh Arora (DIN: 10682240)** who was appointed as Additional Director by the Board of Directors of the Company at their meeting held on 25/06/2025 and who holds office up to the date of this Annual General Meeting be and is hereby appointed as the Director of the Company**."**

By Order of the Board
For Sceptre Medical Devices Private Limited

YOGESH SACHDEVA
(Director)
DIN: 00077095

KARTIK PALTA
(Director)
DIN: 01543913

Place: Delhi
Date: 16.07.2025

Explanatory Statement to the Special Business pursuant to the provisions of Section 102(2) of the Companies Act, 2013:

As required by Section 102 of the Companies Act, 2013 the following statement sets out all material facts relating to the Special Business mentioned in the accompanying notice and should be taken as forming part of the same.

Item No. 2

The Board of Directors of the Company in their meeting held on 25/06/2025 appointed **Mr. Sukesh Arora (DIN: 10682240)** as an Additional Director of the Company pursuant to the provisions of section 161 of the Companies Act, 2013 read with Companies (Appointment & Qualification of Director) Rules ,2014 and in terms of the Articles of Association of the Company. Hence, he will hold office upto the date of ensuing annual General Meeting of the Company.

The Board considers that his association would be of immense benefit to the Company and it is advantageous to have Mr. Sukesh Arora on Board. Accordingly, The Board recommends the resolution for approval of shareholders of the Company.

None of the Directors, Key managerial Personnel or their relatives other than Mr. Sukesh Arora (DIN: 10682240), is concerned or interested financially or otherwise in the proposed resolution.

By Order of the Board
For Sceptre Medical Devices Private Limited

YOGESH SACHDEVA
(Director)
DIN: 00077095

KARTIK PALTA
(Director)
DIN: 01543913

Place: Delhi
Date: 16.07.2025

NOTES:

1. A member entitled to attend and vote is entitled to appoint a proxy or proxies to attend and, on a poll, to vote on his behalf and the proxy need not be a member. A person can act as a proxy on behalf of members not exceeding 50 and holding in the aggregate not more than 10% of the total Share Capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a member holding more than 10% of the total Share Capital of the Company carrying voting Rights, than such proxy shall not act as a proxy for any other person member.
2. The Notice is being sent to all the Members along with the copy of the Annual Report including the Financial Statements, Boards Report etc.
3. All documents referred to in the accompanying Notice are open for inspection at the Registered Office of the Company on all working days, except Sundays between 10.00 A.M. and 2.00 P.M up to the date of the Annual General Meeting.
4. Corporate Members intending to send their authorized representatives are requested to send a duly certified copy of the Board Resolution authorizing their representatives to attend and vote at the Annual General Meeting.

SCEPTRE MEDICAL DEVICES PRIVATE LIMITED

21 Central Market, Ashok Vihar, Delhi, India -110052
CIN: U33100DL2002PTC113888
Email: yogesh_m72@yahoo.com Telephone: 9811093036

DIRECTORS REPORT FOR THE FINANCIAL YEAR 2024-2025

To,
The Members,
Sceptre Medical Devices Private Limited

The Board of Directors are pleased to present the 23rd (Twenty Third)) Annual Report and the Company's Audited Financial Statements for the financial year ended March 31, 2025.

1. Financial Results

The Company's financial performance for the year ended March 31, 2025 is summarized below:

Amount in Rs.

	Year Ended 31.03.2025	Year Ended 31.03.2024
Net Sales/ Receipts	128982490	120364072
Total Expenditure	126091811	116685492
Profit before taxes	2890679	3678580
Less:Provision for Tax		
Current Tax	1400000	750000
Deferred Tax	201170	848115
Profit after taxes	1289509	2080465
Earnings per share	1.39	2.24

2. Financial Highlights

The Highlight of the Company's performance for the year ended 31st March 2025, are as under:

The Profit after Tax is Rs. 1289509 as compared to Rs. 2080465 in the previous year.

3. Dividend

The Board of Directors of your Company have not recommended any dividend for the Financial Year ended 31st March 2025.

4. **Change in the nature of business and Material changes between the date of the board report and end of financial year**

There has been no change in the nature of business of the Company.

There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year and the date of this report.

5. **Subsidiary & Associate Company**

As on March 31, 2025, the Company does not have any subsidiary/joint venture/associate companies.

As on March 31, 2025, M/s **SCEPTRE MEDICAL DEVICES PRIVATE LIMITED (CIN: U33100DL2002PTC113888)** becomes Associate company of Sceptre Medical (INDIA) Private Limited (CIN: U33112DL2010PTC204626)

6. **Directors Responsibility Statement**

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors confirm that:

i) in the preparation of the annual accounts of the year ended March 31, 2025, the applicable accounting standards have been followed along with proper explanations relating to any material departures, if any;
ii) they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2025 and of the profit of the Company for the year ended on that date;
iii) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
iv) that the Annual Accounts are prepared on a going concern basis;
v) that they have laid down proper internal financial controls to be followed by the company and that internal financial controls are adequate and are operating effectively; and

vi) they have devised proper systems to ensure compliance with the provisions of all applicable laws and these systems are adequate and operating effectively.

7. Related Party Transactions

Related party transactions were entered into by the Company during the financial year. Related party transactions entered by the Company during the financial year were in the ordinary course of business and on arm's length basis which did not conflict with the interest of the Company.

8. Corporate Social Responsibility Policy and related Disclosures/Compliances

The Company does not cross the threshold limit provided under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 relating to Corporate Social Responsibility, hence CSR is not applicable to the Company.

9. Risk Management

The Board has adopted the procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting record, and the timely preparation of reliable financial disclosures.

10. Internal Financial Controls System and their Adequacy

The Company has in place adequate systems of internal controls to ensure compliance with policies and procedures, including monitoring procedures to ensure that all assets and investments are safeguarded against loss from unauthorized use or disposition.

11. Directors and Key Managerial Persons

There has been change in the constitution of Board during the period under review.

Mr. Sukesh Arora (DIN: 10682240) was appointed as an Additional Director of the Company with effect from **25.06.2025** whose appointment will be regularised in this Annual General Meeting

Particulars of remuneration in terms of Section 197(12) of the Act and Rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are applicable to listed public companies. Your Company being a private limited company hence the same has not been provided in the report.

12. **Secretarial Audit**
Provisions of Section 204 of the Companies Act, 2013 relating to Secretarial Audit is not applicable to your company.

13. **Auditor and Explanation on Auditor Qualification:**

Pursuant to the provisions of the section 139 of the Act and the rules framed there under, M/s. RGMG & CO., Chartered Accountants (FRN: 006329N) were appointed as Statutory Auditors of the Company to hold office till the conclusion of AGM of the Company to be held in the year 2029. Auditor's Report for the current financial year is annexed herewith for your kind perusal and information.

The report of the Statutory Auditors along with notes to Schedules is enclosed to this Report. The statutory Auditors report submitted by them does not contain any qualifications, reservations, adverse remarks or disclaimers on the financial statements of the Company for the financial year 2024-2025.

14. **Number of meetings of the Board**
6 Meetings of the Board of Directors were held during the year. The meetings were held on 16.04.2024, 16.07.2024, 18.09.2024, 12.12.2024, 28.01.2025 and 07-03-2025. All the directors of the company attended all the meetings.

15. **Deposits**

The company has not accepted any deposits u/s 73 of Companies Act, 2013 during the year under review.
The Company has not accepted loan from directors or relative of the director of the Company or any other companies during the year.

16. **Transfer to Reserve**
The Board of Directors does not propose to transfer any profits to any reserve.

17. **Significant and Material Orders Passed by the Regulators**
During the year under review, there were no significant or material orders which were passed by the regulators or courts or tribunals which may impact the going concern status and company's operation in future.

18. **Declaration by Independent Director**

Provisions of Section 149 relating to Independent Directors is not applicable to your Company, therefore, no statement on declaration to be given by independent directors is being enclosed herewith.

19. Changes in Share Capital

The paid-up Equity Share Capital as on 31st March 2025 was Rs. 93,00,000/. There was change in the share capital of the Company during the year under review.

20. Inter Corporate Loans and Investments

There was no loans, guarantee and investment made by the Company under section 186 of the Companies Act, 2013 during the year, under review and hence the said provisions are not applicable.

21. Transfer of unclaimed/unpaid amount to Investor Education and Protection Fund

During the Financial Year 2024-2025, no amount was required to be transferred to the Investor Education and Protection Fund.

22. Particulars regarding Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Expenditure

Since the company carries out manufacturing activity, the particulars relating to conservation of energy, technology absorption and other particulars required pursuant to Section 134(3) (m) read with Rule 8 (3) of the Companies (Accounts) Rules, 2014 are applicable to Company.
Details of the same are enclosed in Annexure-II

There were foreign exchange earnings and expenditures. Therefore the directors have report on the foreign exchange earnings and outgo pursuant to Section 134(3) (m) of the Companies Act, 2013.
Details of the same are enclosed in Annexure-II

23. Web Link of Annual Return

Pursuant to Section 92(3), Company https://www.sceptremedica.in has a Website, a copy of Annual Return will be placed on the website of the Company.

24. Instances of Fraud Reported by the Auditors

There have been no instances of fraud reported by the Auditors under Section 143(12) of the Act.

25. MATERNITY COMPLIANCE DISCLOSURE:

The Company confirms that as on 31st March, 2025, The Maternity Benefit Act,1961 is not applicable to Company because there were no employees who were eligible for maternity leave during financial year Accordingly no **maternity leave, medical benefits, nursing breaks** were availed or provided during the year.

26. Statutory disclosures

The directors' responsibility statement as required by section 134(5) of the Companies Act, 2013, reports above.

The provisions of section 148 of the Companies Act, 2013, are not applicable to the Company. Accordingly, there is no requirement of maintenance of cost records as specified under sub-section (1) of section 148 of the Companies Act, 2013.

Pursuant to the legislation 'The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013', the Company has a policy on Prevention of Sexual Harassment at Workplace. During the year under review, no complaint was received from any of the employees,

Neither any application was made nor any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the financial year.

Loans were taken from banks or Financial Institutions but there are no disclosure relating to details of difference between the amount of valuation done at the time of one-time settlement and valuation done while taking loan from the Banks or Financial Institutions.

Loans received from Directors are from their Owned Funds not from Borrowed funds.

27. SECRETARIAL STANDARDS

The Directors state that the Company has complied with both the applicable Secretarial Standards i.e. SS- 1 and SS-2 relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively.

28. **Disclosure Under SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013**

The Company has in place `Prevention of Sexual Harassment Policy` in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. An Internal Complaints Committee (ICC) is in place to redress complaints received regarding sexual harassment.

The following is a summary of sexual harassment complaints received and disposed off during the year,
-No. of complaints received: Nil,
-No. of complaints disposed off: NA.

29. COMPLIANCES OF ALL LAWS

The Board hereby states that the company has devised proper systems to ensure compliance of all laws applicable to the company.

30. Appreciation

Your Directors wish to place on record their sincere appreciation to the shareholders, employees and bankers for their co-operation and support.

By Order of the Board
For Sceptre Medical Devices Private Limited

YOGESH SACHDEVA	KARTIK PALTA
(Director)	(Director)
DIN: 00077095	DIN: 01543913

Place: Delhi
Date: 16.07.2025

ANNEXURE-I

FORM NO. AOC-2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

1. Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	M S Medicals Medical Private Limited and related through Director
2	Nature of contracts/arrangements/transactions	Purchase and Sale of Goods
3	Duration of the contracts/arrangements/transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Purchase = Rs 4111803 Sale = Rs 47340243
5	Date of approval by the Board, if any	16.04.2024
6	Amount paid as advances, if any	-----

2. Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Sceptre Medical (India) Private Limited and related through Director
2	Nature of contracts/arrangements/transactions	Purchase and Sale of Goods
3	Duration of the contracts/arrangements/transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transaction = Purchase = Rs 49650 Sale = Rs 53390
5	Date of approval by the Board, if any	16.04.2024
6	Amount paid as advances, if any	-----

3. Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr. Kartik Palta Director
2	Nature of contracts/arrangements/transactions	Remuneration
3	Duration of the contracts/arrangements/transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 1350000
5	Date of approval by the Board, if any	16.04.2024
6	Amount paid as advances, if any	-----

4. Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr Sanjay Manocha Director
2	Nature of contracts/arrangements/transactions	Remuneration
3	Duration of the contracts/arrangements/transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 900000
5	Date of approval by the Board, if any	16.04.2024
6	Amount paid as advances, if any	-----

5. Details of material contracts or arrangement or transactions at arm's length basis

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr Yogesh Sachdeva Director
2	Nature of contracts/arrangements/transactions	Remuneration
3	Duration of the contracts/arrangements/transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 900000
5	Date of approval by the Board, if any	16.04.2024
6	Amount paid as advances, if any	-----

S.No	Particulars	Details
1	Name(s) of the related party and nature of relationship	Mr Sattvik Palta Director's son
2	Nature of contracts/arrangements/transactions	Remuneration
3	Duration of the contracts/arrangements/transactions	One Year
4	Salient terms of the contracts or arrangements or transactions including the value, if any	Value of Transactions: Rs 270000
5	Date of approval by the Board, if any	16.04.2024
6	Amount paid as advances, if any	-----

For and on the behalf of Board of Directors
Sceptre Medical Devices Private Limited

YOGESH SACHDEVA

(Director)

DIN: 00077095

KARTIK PALTA

(Director)

DIN: 01543913

Place: New Delhi
Date: 16.07.2025

SCEPTRE MEDICAL DEVICES PRIVATE LIMITED

21 Central Market, Ashok Vihar, Delhi, India -110052

CIN: U33100DL2002PTC113888

Email: yogesh_m72@yahoo.com Telephone: 9811093036

ANNEXURE-II

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO

(A) Conservation of Energy:

1. Steps taken for conservation of energy and impact:

The Company has taken various measures for conservation of energy, details of which are as under:

- **HVAC System Optimization:** Optimization of Air Handling Units (AHUs) and cleanroom utilities to improve energy efficiency and reduce power consumption.
- **Process Equipment Efficiency:** Use of energy-efficient machinery and preventive maintenance practices to minimize energy loss during pharmaceutical manufacturing.
- **Lighting Efficiency:** Replacement of conventional lighting with LED lighting across production areas, laboratories, and warehouses.
- **Compressed Air Management:** Regular monitoring and maintenance of compressed air systems to reduce leakages and avoid energy wastage.

Impact:
These initiatives have helped in optimizing power consumption and resulted in overall reduction in energy costs and improved operational efficiency.

2. Steps taken by the Company for utilizing alternate sources of energy:

At present, the Company has not installed or utilized any alternate source of energy, including solar power or other renewable energy sources. However, the Company continues to evaluate feasible options for adopting alternate and renewable energy sources as part of its long-term sustainability and cost-optimization strategy.

3. Capital investment on energy conservation equipment:

The Company has made capital investments in energy-efficient equipment and utility optimization, including:

- Installation of energy-efficient motors and utility equipment.
- Improvement in monitoring and control systems for utilities to reduce energy consumption.

These investments support efficient energy utilization across manufacturing operations.

B) Technology Absorption, Adaptation and Innovation

1. Efforts made towards technology absorption:

The Company continues to focus on absorption and adaptation of modern technologies to enhance efficiency, quality, and regulatory compliance in pharmaceutical manufacturing. Key initiatives include:

- **Process Optimization:** Adoption of improved manufacturing processes and validated production techniques to enhance product consistency, yield, and efficiency.
- **Automation & Digital Controls:** Increased use of PLC-based controls and automated systems in critical manufacturing and utility operations to reduce manual intervention and improve process reliability.
- **Quality & Compliance Systems:** Strengthening of Quality Management Systems (QMS) in line with GMP requirements, including upgraded laboratory instruments and improved documentation and traceability systems.
- **Regulatory Alignment:** Continuous upgradation of systems and procedures to comply with evolving regulatory requirements under Indian and international pharmaceutical standards.

2. Benefits derived from technology absorption:

The above initiatives have resulted in the following benefits:

- Improved manufacturing efficiency and reduced process variability.
- Enhanced product quality, safety, and regulatory compliance.

- Reduction in production downtime and operational costs.
- Better utilization of resources and improved overall productivity.

3. Information regarding technology imported during the last three years:

The Company has not imported any specific technology during the last three financial years. The technological improvements have been achieved primarily through in-house process development, optimization of existing machinery, and adoption of best industry practices.

C) FOREIGN EXCHANGE EARNINGS AND OUTGO

S.No.	PARTICULARS	31.03.2025
1	Value of Imports on CIF basis	3,99,05,243
2	Expenditure in Foreign Currency	
	Outward Remittance	3,80,45,566
	Travel Expenditure	2,12,040
3	Consumption of imported Raw Material components and spare parts	3,87,84,998
4	Earning in foreign Currency	17077

For and on the behalf of Board of Directors
Sceptre Medical Devices Private Limited

YOGESH SACHDEVA
(Director)
DIN: 00077095

KARTIK PALTA
(Director)
DIN: 01543913

Place: New Delhi
Date: 16.07.2025

SCEPTRE MEDICAL DEVICES PRIVATE LIMITED

21 Central Market, Ashok Vihar, Delhi, India -110052

CIN: U33100DL2002PTC113888

Email: yogesh_m72@yahoo.com Telephone: 9811093036

Dated: 24.01.2026

To

Registrar of Companies

4th Floor, IFCI Tower,61, Nehru Place,

New Delhi-110019

Subject: Conversion Of Sceptre Medical (INDIA) Private Limited to **Sceptre Medical (INDIA) Limited**

Sir/Mam

Sceptre Medical (INDIA) Private Limited having CIN: U33112DL2010PTC204626 is an entity which enters into contracts or arrangement or transactions at arm's length basis with SCEPTRE MEDICAL DEVICES PRIVATE LIMITED having CIN: U33100DL2002PTC113888 by virtue of Sale and Purchase of goods.

Sceptre Medical (INDIA) Private Limited is converted into **Sceptre Medical (INDIA) Limited having CIN: U33112DL2010PLC204626 vide SRN AC1382823 dated 19/01/2026.**

Kindly consider it .

Thanking you

YOGESH SACHDEVA	**KARTIK PALTA**
(Director)	(Director)
DIN: 00077095	DIN: 01543913

RGMG & CO.
CHARTERED ACCOUNTANTS
120, Rajendra Bhawan, Rajendra Place,
New Delhi-110 008 Phone : (91)-(11) 2576 1681
Email : rajesh@rgmg.org, manoj@rgmg.org

INDEPENDENT AUDITORS' REPORT

To, The Members
Sceptre Medical Devices Private Limited

Report on the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Sceptre Medical Devices Private Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2025, and the Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. *Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report.* We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

RGMG & CO. New Delhi FRN 008320N Chartered Accountants

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Information other than the financial statements and auditors' report thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report, but does not include the standalone financial statements and our auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls systems in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to

RGMG & CO. New Delhi FRN 006329N Chartered Accountants communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. Being a small Company, the provisions of the Companies (Auditor's Report) Order,2020 ('the Order") issued by the Central Government in terms of section 143(11) of the Act is not applicable to the Company.

2. As required by Section 143 (3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules,2015 as amended.

e) On the basis of the written representations received from the directors as on 31st March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.

f) Since the Company's turnover as per last audited financial statements is less

RGMG & Co. New Delhi FRN-[illegible]329N Chartered Accountants than Rs. 50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs 25 Crore, the Company is exempted from getting an audit opinion with respect to the adequacy of the financial controls over financial reporting of the Company and the operating effectiveness of such controls vide notification dated June 13, 2017; and

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

   i. The Company does not have any pending litigations which would impact its financial position.

   ii. The company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

   iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

   iv. a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

   b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding,

RGMG & CO. New Delhi FRN 0?329N Chartered Accountants whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.

v. The company has not declared or paid dividend during the year.

vi.. Based on our examination which included test checks the Company has used accounting software maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software. Further, for the periods where audit trail (Edit Log) facility was enabled and operated throughout the year for the respective accounting software, we did not come across any instance of the audit trail feature being tampered with.

For RGMG & CO.
Chartered Accountants
FRN No. 006329N

RGMG & CO. New Delhi FRN 006329N Chartered Accountants

Manoj Gupta
Partner
Membership No. 096116
Place: New Delhi
Date: 16.07.2025
UDIN: 25096116BMGXYA3068

Sceptre Medical Devices Private Limited
Balance Sheet as at 31st March, 2025

In Rs.,000

Particulars	Note No	2025	2024
1	2	3	4
I. EQUITY AND LIABILITIES			
Shareholders' funds			
Share Capital	2	9300.00	9300.00
Reserve and Surplus	3	11252.16	10314.67
Non-Current Liabilities			
Long-Term Borrowings	4	28623.77	37626.91
Long Term Provisions	5	4949.76	2691.29
Current liabilities			
Short-Term borrowings	6	35510.03	34116.19
Trade Payables	7	4838.73	2815.54
Other Current Liabilities	8	5266.41	4680.67
Short Term Provisions	9	1193.84	683.69
TOTAL		**100934.69**	**102228.94**
II. ASSETS			
Non-Current Assets			
Property,Plant and Equipment	10	38144.02	35805.47
Other Non Current Assets	11	200.96	200.96
Current Assets			
Inventories	12	38775.66	25778.87
Trade Receivable	13	7316.61	14487.19
Cash and Cash Equivalents	14	1874.04	13394.92
Short-Term Loans and Advances	15	11785.04	10166.07
Other Current Assets	16	2838.36	2395.46
TOTAL		**100934.69**	**102228.94**

Significant Accounting Policies Notes on Financial Statements 1 to 24

As per our report of even date
For RGMG & CO.
Chartered Accountants
Firm Regn No.006329N

M Gupta
Manoj Gupta
Partner, M.No. 096116
New Delhi

RGMG & CO. New Delhi FRN 006329N Chartered Accountants

For and on behalf of the Board

Sanjay Manocha
Director
DIN:00076997

Kartik Palta
Kartik Palta
Director
DIN:01543913

Yogesh Sachdeva
Director
DIN:00077095

Sceptre Medical Devices Private Limited

Statement of Profit & Loss for the year ended 31st March, 2025

In Rs.,000

	Particulars	Note No	2025	2024
	Income:			
I	Revenue from operations	17	128913.04	120315.27
	Other income	18	69.45	48.80
	Total Income (I+II)		**128982.49**	**120364.07**
II	**Expenses:**			
	Cost of Material Consumed	19	87670.83	78013.77
	Change in inventories of Stock-in-Tra	20	-4824.36	-436.13
	Employee benefits expenses	21	23844.34	19346.92
	Finance costs	22	4896.91	3867.01
	Depreciation and amortization expens	23	3208.15	2881.20
	Other Expenses	24	11295.94	13012.73
	Total expenses		**126091.81**	**116685.49**
III	**Profit before tax (I-II)**		2890.68	3678.58
IV	**Tax expenses:**			
	Current Tax		1400.00	750.00
	Deferred Tax		201.17	848.12
V	**Profit (Loss) for the period (III-IV)**		1289.51	2080.47
VI	**Earning per equity share:**			
	Basic & Diluted		1.39	2.24

Significant Accounting Policies Notes on Financial Statements 1 to 24

As per our report of even date

For RGMG & CO.
Chartered Accountants

Manoj Gupta
Partner, M.No. 096116
New Delhi

RGMG & CO. New Delhi Chartered Accountants

For and on behalf of the Board

Sanjay Manocha
Director
DIN:00076997

Kartik Palta
Director
DIN:01543913

Yogesh Sachdeva
Director
DIN:00077095

Sceptre Medical Devices Private Limited

Notes forming part of the Financial Statements for the year ended March 31,2025

1 SIGNIFICANT ACCOUNTING POLICIES

1.1 Corporate Information

Manocha Medical Private Limited("the Company) was incorporated on 18th January, 2002 under the Companies Act,1956 as a Private Limited Company. The company has changed it name with permission of Ministry of corporate affair (MCA) from Manocha Medical Private Limited to Sceptre Medical Private Limited on 06/04/2018.The Company is engage in the business of Medicines, Pharmaceuticals, Surgical Equipment's, Surgicals disposable goods and medical related chemicals.

1.2 Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the generally accepted accounting principals in India under the historical cost convention on accrual basis. Pursuant to section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014, till the standards of accounting or any addendum thereto are prescribed by central Government in consultation and recommendation of the National Financial Reporting Authority, the existing Accounting Standards notified under the Companies Act, 1956 shall to apply. Consequently, these financial statements have been prepared to comply in all material aspects with the accounting standards notified under section 211(3C) of Companies Act, 1956 (Companies (Accounting Standards) Rules 2006, as

1.3 Use of Estimates

The preparation of financial statement requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognised in the period in which the results are known/materialised.

1.4 Cash and Cash equivalents

Cash comprises cash on hand and demand deposits with banks, Cash equivalents are short term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

1.5 Cash Flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financial activities of the company are segregated based on the available information.

1.6 Property, Plant & Equipment and Intangible Assets

Tangible Assets are stated at cost, less accumulated depreciation and impairment losses if any. Costs includes all expenses incurred to bring the assets to its present location and condition.

RGMG & CO. New Delhi FRN [illegible]329N Chartered Accountants

Intangible Assets are stated at cost, less accumulated depreciation and impairment losses if any. Costs includes all expenses incurred to bring the assets to its present location and condition.

1.7 Depreciation and Amortisation

Depreciation on Tangible and Intangible Assets is provided on a Straight Line method, over the estimated useful life of the Asset in the manner prescribed in Schedule II of the Act. Depreciation on additions to assets or on sale / discernment of assets, is calculated prorate basis from the month of such addition or up to the month of such sale/discardment, as the case may be.

1.8 Impairment of Assets

An Asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged in Profit & Loss Account in the year in which an assets is identified as impaired. The impairment loss recognised in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

1.9 Foreign Currency Transactions

Purchase and services revenue are accounted at daily basis. Exchange Fluctuations arising on payment or on realization are dealt with in the statement of Profit & Loss. Monetary Assets and Liabilities are restated at the year end closing rate and any difference arising there of has been dealt with in the statement of Profit & Loss to the extent its pertains to the current year.

1.10 Investments

Current Investments are carried at lower of cost and quoted/ fair value, computed category wise. Long Term Investment are stated at cost. Provisions for diminution in the value of long term investment is made only if such a decline is other than temporary.

1.11 Inventories

Items of inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any.

1.12 Revenue Recognition

Revenue is recognized only when it can be reliably measured and it is reasonable to expect ultimate collection. Revenue from operations includes sale of goods, services, sales tax, service tax, excise duty and sales during trial run period, adjustment for discounts (net), Value Added Tax (VAT) and gain/loss on corresponding hedge contracts. Dividend Income is recognised when right to receive is established. Interest income is recognised on time proportion basis taking into account the amount outstanding and rate applicable.

1.13 Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to Profit & Loss Account.

RGMG & CO.
New Delhi
FRN-006329N
Chartered Accountants

1.14 Earning Per Share

Basic Earning per Share is computed by dividing Profit after tax (including the post tax effect of extraordinary items, if any) by the number of equity share outstanding during the

1.15 Provisions for Current and Deferred Tax

Provisions for current tax is made after taking into consideration benefits admissible under the provisions of the Income Tax Act,1961. Deferred tax resulting from "timing difference" between taxable and accounting income is accounted using the tax rates and laws that are enacted or substantively enacted as on the balance sheet date. Deferred tax assets is recognised and carried forward only to the extent that there is a virtual certainty that the asset will be realised in future

1.16 Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognised but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

1.17 Note on Provision for Gratuity and Leave Encashment

The Company had not made any provision towards gratuity and leave encashment liability in the earlier years since its incorporation. During the financial year 2024-25, the Company has obtained an actuarial valuation of gratuity and leave encashment liability from a registered valuer in accordance with the requirements of Accounting Standard (AS) 15 *"Emplouee Benefits"*.

The Company had not made any provision towards gratuity and leave encashment liability in the earlier years since its incorporation. During the financial year 2024-25, the Company has obtained an actuarial valuation of gratuity and leave encashment liability from a registered valuer in accordance with the requirements of Accounting Standard (AS) 15 *"Emplouee Benefits"*.

Based on the actuarial valuation as at March 31, 2025, the following provisions have been recognized in the financial statements for the first time:

Gratuity Liability: Rs. 15,69,388

Leave Encashment Liability: Rs. 5,38,576

Accordingly, the total provision of Rs.21,07,964 has been created and charged to the Statement of Profit and Loss for the year ended March 31, 2025.

Management believes that the recognition of such liabilities in the current year appropriately represents the Company's obligation towards its employees as at the balance sheet date.

1.18 The MCA Vide Notification dated 24th March 2021 has amended Schedule III to the Companies Act, 2013 in respect of certain disclosers are applicable from 1st April, 2021. The Company incorporated the changes as per the said amendment in the financial statements and below disclosers are made in compliance of the said amendments.

(I) The Companies has no transactions with Companies Struck off under section 248 of the

RGMG & CO. New Delhi Chartered Accountants

Companies Act, 2013 or Section 560 of the Companies Act,1956 during the year

(ii) The Company has not traded or invested in Crypto Currency or Virtual Currency during the year.

(iii) The Company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami Property.

(iv) The Company do not have any charge or satisfaction which is yet to be registered with ROC beyond the statutory period.

(v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(vi) The Company have not received any funds from any person(s) or entity(ies). Including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(vii) The Company does not have any loans and advances in the nature of loans to promoters, directors, KMP and other related parties.

1.19 Additional Information:

Rs. In ,000

Sr No.	**Particulars**	**31.03.25**	**31.03.24**
01	Value of Imports on CIF basis	3,99,05.243	4,68,87.114
02	Expenditure in Foreign Currency		
	- Outward Remittance	3,80,45.566	4,00,01.214
	- Travel Expenditure	2,12.040	1,19.517
03.	Consumption of imported Raw Material components and spare parts	3,87,84.998	3,03,97.751
04	Earning in foreign Currency	17.077	2,01.502
05	Amount remitted in foreign currency towards Dividend	--	--

RGMG & CO. New Delhi FRN-[illegible]329N Chartered Accountants

1.19 Disclosure as per Accounting Standard - 18 on 'Related Party Disclosures'

Following are the related parties and transactions made with them during the year.

- Key Management Personnel (KMP)	:	Mr. Sanjay Manocha
Director of the Company	:	Mr. Yogesh Sachdeva
		Mr. Kartik Palta
- Entities in which KMP/Relatives of KMP	:	M S Medicals Private Limited
can exercise significant influence	:	Sceptre Medical (India) Pvt Ltd

Detail of related party transactions during the year ended 31 March, 2025

		2025	2024 (Rs.)	
Mr. Kartik Palta (Remuneration)		1350.00	1800.00	
Mr Sanjay Manocha (Remuneration)		900.00	1200.00	
Mr Yogesh Sachdeva (Remuneration)		900.00	1200.00	
Purchase of Good				
M S Medicals Medical Private Limited		4111.80	2310.30	
Sceptre Medical (India) Private Limited		49.65	84.25	
Sale of Goods				
M S Medicals Medical Private Limited		47340.24	43620.76	
Sceptre Medical (India) Private Limited		53.39	32.03	
Balance outstanding at the end of the year				
M S Medicals Medical Private Limited	DR	1823.08	5695.01	DR
Sceptre Medical (India) Private Limited		-	18.85	CR

1.20 Detail of Current Maturities of Long Term Borrowings as below:

		Long Term	Short Term	Total
1	Deutsche Bank	2162.54	953.18	3115.72
2	HDFC Bank	.00	239.56	239.56
3	Kotak Mahindra Bank	1080.72	306.99	1387.71
4	Yes Bank	2335.79	1211.25	3547.04
5	SIDBI-366O	.00	692.83	692.83
6	SIDBI-3B33	.00	447.96	447.96
8	SIDBI-3ZT6	1070.00	1260.00	2330.00
9	SIDBI-D0005ZQG	4265.00	2220.00	6485.00
10	SIDBI-S00070AM	8675.00	3300.00	11975.00
		19589.05	**10631.76**	**30220.81**

RGMG & CO. New Delhi FRN [illegible]329N Chartered Accountants

1.4 Key Financial Ratios are as below:

In Rs.,000

Sr.No	Ratio	Current Year Numerator	Current Year Denominator	Current Year Ratio	Previous Year Numerator	Previous Year Denominato	Previous Year Ratio	% Variance
1	**Current Ratio**							
	Current Assets / Current Liabilities							
	Current Assets							
	Inventories	38775.66			25778.87			
	Trade receivable	7316.61			14487.19			
	Cash and cash equivalents	1874.04			13394.92			
	Short-term loans and advances	11785.04			10166.07			
	Other Current Assets	2838.36			2395.46			
	Total	**62589.71**			**66222.51**			
	Current Liabilities							
	Trade payables		4838.73			2815.54		
	Cash Credits		24878.27			22460.90		
	Short Term Loans		10631.76			11655.29		
	Other current liabilities		5266.41			4680.67		
	Provision for Taxation		1193.84			683.69		
	Total		**46809.00**	**1.34**		**42296.07**	**1.57**	-14.60
2	**Debt-Equity Ratio**							
	Total Debts / Shareholders Equity							
	Debts							
	Long-term borrowings	28623.77			37626.91			
	Short-term borrowings	35510.03			34116.19			
		64133.79			**71743.10**			
	Shareholders Equity							
	Share Capital		9300.00			9300.00		
	Reserve and surplus		11252.16			10314.67		
			20552.16	**3.12**		**19614.67**	3.66	-14.68
3	**Debt Service Coverage Ratio**							
	Earning available for debts service / Debts Service							
	Earning for Debts Services							
	Net Profit before Taxes	2890.68			3678.58			
	Add: Depreciation	3208.15			2881.20			
	Interest	4896.91			3867.01			
	Total	**10995.74**			**10426.79**			
	Debts Service							
	Interest Payment		4896.91			3867.01		
	Principal =Short Term & Long -term		11655.29			7882.44		
			16552.20	**0.66**		**11749.45**	0.89	-25.14
4	**Return on Equity Ratio**							
	Net Profit after Taxes / Shareholder Equity							
	Net Profit After Tax	1289.51			2080.47			
		1289.51			**2080.47**			
	Shareholders Equity							
	Share Capital		9300.00			9300.00		
	Reserve and surplus		11252.16			10314.67		
			20552.16	0.0627		**19614.67**	0.106	-40.85

RGMG & CO.
New Delhi
FRN:-008329N
Chartered Accountants

5	**Inventory Turnover Ratio**							
	Cost of Goods Sold/Sales							
	Average Turnover							
	Cost of Goods Sold							
	Cost of Material Consumed	87670.83			78013.77			
	Purchase of Stock-in-Trade	-			-			
	Change in Inventory of Stock	-4824.36			-436.13			
	Employee Benefit Expenses	23844.34			19346.92			
	Consumable	452.48			466.47			
	Job Work Charges	337.60			80.87			
	Custom Duty	1468.76			1909.10			
	Freight	1948.53			1739.56			
	Clearing & Forwarding Expenses	720.24			863.19			
	Repair & Maintenance Charges	654.36			569.22			
	Power & Fuel	1702.69			1378.31			
	Product Testing Fee	-			14.00			
	Total	**113975.49**			**103945.26**			
	Average Turnover							
	Opening Stock		25778.87			20541.35		
	Closing Stock		38775.66			25778.87		
	Total		**64554.53**			**46320.22**		
	Average Turnover		**32277.27**	3.53114		**23160.11**	4.49	-21.32
6	**Trade Receivable Turnover Ratio**							
	Net Credit Sales							
	Average Accounts Receivable							
	Net Credit Sales							
	Sales less Sales Return	128913.04			120315.27			
		128913.04			**120315.27**			
	Average Account Receivable		14487.19			13513.30		
	Opening Balance		7316.61			14487.19		
	Closing Balance		**21803.80**			**28000.49**		
	Average Account Receivable		**10901.90**	11.8248		**14000.24**	8.59	37.60
7	**Trade Payable Turnover Ratio**							
	Net Credit Purchases							
	Average Accounts Payable							
	Net Credit Purchases							
	Purchases less Purchases Return(Mfd)	95843.27			82815.16			
	Purchases less Purchases Return(Trad,)	-			-			
	Total	**95843.27**			**82815.16**			
	Average Account Payable							
	Opening Balance		2815.54			2763.82		
	Closing Balance		4838.73			2815.54		
	Average Account Payable		**7654.27**			**5579.35**		
			3827.13	25.0431		**2789.68**	29.69	-15.64
8	**Net Capital Turnover Ratio**							
	Net Sales							
	Net Working Capital							
	Net Sales	128913.04			120315.27			
	Net Working Capital							
	Current Assets		62589.71			66222.51		
	Less: Current Liabilities		46809.00			42296.07		
			109398.72	1.17838		**108518.58**	1.11	6.28

RGMG & CO.
New Delhi
FRN:-006329N
Chartered Accountants

9	**Net Profit Ratio**							
	Net Profit / Sales							
	Net Profit (After Taxes)	1289.51			2080.47			
	Total	**1289.51**			**2080.47**			
	Sales		129379.47			120315.27		
	Total		**129379.47**	0.0100		**120315.27**	0.017	-42.36
10	**Return on Capital Employed**							
	Earning before Interest and Taxes / Capital Employed							
	Earning before Interest and Taxes							
	Net Profit	2890.68			3678.58			
	Add: Interest	4896.91			3867.01			
	Total	**7787.59**			**7545.59**			
	Capital Employed							
	(Total Assets -Current Liabilities)							
	Total Assets		100934.69			102228.94		
	Less: Current Liabilities		46809.00			42296.07		
			54125.69	0.14388		**59932.86**	0.126	14.28
11	**Return on Investment**							
	Profit / Investment	-	-	-	-	-	-	

Reason for Variance

1 There is no significant change in the key financial ratio (Less than 25%)
2 There is no significant change in the key financial ratio (Less than 25%)
3 Earning for Debts Service increased in Current Year, therefore ratio increased.
4 Profit in Current Year decreased as compare to previoud Year, therefore ratio decresaed.
5 There is no significant change in the key financial ratio (Less than 25%)
6 Net Credit Sales increased in Current Year, therefore ratio increased.
7 There is no significant change in the key financial ratio (Less than 25%)
8 There is no significant change in the key financial ratio (Less than 25%)
9 Profit in Current Year decreased as compare to previoud Year, therefore ratio decresaed.
10 There is no significant change in the key financial ratio (Less than 25%)
11 There is no earning from Investment

RGMG & CO.
New Delhi
FRN:-006329N
Chartered Accountants

Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024

The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation

2. SHARE CAPITAL

	2025	2024
Authorized Share Capital :		
1000000 Equity shares of Rs.10/- each	10000.00	10000.00
(Previous Year 1000000 Equity Shares)		
Issued, Subscribed and Paid up :		
930000 Equity Shares of Rs.10/- each fully paid up	9300.00	9300.00
(Previous Year 930000 Equity Shares of Rs.10/- each)		
Total	**9300.00**	**9300.00**

The details of Shareholders holding more than 5% Shares:

Name of the Shareholders	2025		2024	
	No. of Share	% held	No. of Share	% held
Sanjay Manocha	223200	24.00	310001	33.33
Yogesh Sachdeva	156240	16.80	309899	33.32
Kartik Palta	111600	12.00	310000	33.33
Sukesh Arora	66960	7.20	-	-
Sceptre Medical (India) Private Limited	372000	40.00	-	-

The details of Promoters Shareholders as below:

Name of the Promoters	2025		2024	
	No. of Share	% held	No. of Share	% held
Sanjay Manocha	223200	24.00	310001	33.33
Yogesh Sachdeva	156240	16.80	309899	33.32
Kartik Palta	111600	12.00	310000	33.33
Sukesh Arora	66960	7.20	-	-

The Reconciliation of the numbers of shares outstanding is set out below:

		2025	2024
Equity Shares at the beginning of the year		930000	930000
Add: Share Issued during the year		-	-
Equity Shares at the end of the year		930000	930000

Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs.10 per share. All these shares have same rights and preferences with respect to payment of dividend, repayment of capital and voting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

3. RESERVES AND SURPLUS	**2025**	**2024**
Share Premium		
As per Last Balance Sheet	3055.00	3055.00
Add: During the year	-	-
Total (A)	**3055.00**	**3055.00**
Profit & Loss Account		
As per Last Balance Sheet	7259.67	5179.20
Add: Profit for the year	1289.51	2080.47
Less: Previous Year Adj.	352.01	-
Total (B)	**8197.16**	**7259.67**
Grand Total (A+B)	**11252.16**	**10314.67**

RGMG & CO.
New Delhi
FRN:-008329N
Chartered Accountants

Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
4.LONG TERM BORROWINGS		
Term Loan:-Rupee Loan from Bank-Secured	19589.05	24042.20
Loan and Advances from related parties	9034.72	13584.72
Total	**28623.77**	**37626.91**

Security

(i) Term Loans from SiDBI is secured by way of Mortgage of Factory Building, Machinery and Personal Guarantee
(ii) Term Loans from Banks is secured by way of Personal Guarantee of Directors

	2025	2024
5. NON CURRENT PROVISIONS		
Deferred Tax Liabilities(Net)	2892.46	2691.29
Provision for Gratuity	1541.02	-
Provision for Leave Encashment	516.29	-
Total	**4949.76**	**2691.29**

	2025	2024
6.SHORT TERM BORROWINGS		
Cash Credit from Banks -Secured	24878.27	22460.90
Term Loan:-Rupee Loan from Bank-Secured	10631.76	11655.29
Total	**35510.03**	**34116.19**

Security

(i) Working Capital Loans are secured by hypothecation of present and future stock, book debts, material in transit , etc.
(ii) Term Loans from Banks and Financial Institutions is secured by way of specific charge on assets and under Hypothecation relating to automobile financing.

(iii) Term Loans (Other than automobile) from Banks and financial Institutions is secured buy way of personal guarantee of Directors

	2025	2024
7. TRADE PAYABLES		
(i)Micro, Small and Medium Enterprises		
-Less Than 1 Year	-	784.88
-1-2 Years	2035.14	-
-2-3 Years	-	-
- More than 3 Years	-	-
(ii)Others		
-1-2 Years	2803.59	2030.65
(iii) Disputed Dues-MSME	-	-
(iii) Disputed Dues-Others	-	-
Total	**4838.73**	**2815.54**

	2025	2024
8.OTHER CURRENT LIABILITIES		
Advance from Customers	1904.36	1730.92
TDS Payable	60.52	178.05
Expenses Payable	2682.65	2126.48
GST Payable	374.31	392.20
Others	244.58	253.02
Total	**5266.41**	**4680.67**

	2025	2024
9.SHORT TERM PROVISIONS		
Provision for Income Tax	1143.18	683.69
Provision for Gratuity	28.37	-
Provision for Leave Encashment	22.29	-
Total	**1193.84**	**683.69**

RGMG & CO.
New Delhi
FRN:-006329N
Chartered Accountants

Notes on Financial Statement for the year ended 31st March, 2025

10 PROPERTY, PLANT AND EQUIPMENT

In Rs.,000

Particulars	Original Cost				Depreciation				Net Book Value	
	As at 01.04.24	Addition	Ded Adj.	As at 31.03.25	As at 01.04.24	For the Year	Ded Adj.	As at 31.03.25	As at 31.03.25	As at 31.03.24
TANGIBLE ASSETS:										
Factory Building	13848.96	-	-	13848.96	2914.87	439.01	-	3353.89	10495.07	10934.08
Plant & Machinery	29966.05	5441.88	699.88	34708.04	8733.24	2045.76	243.45	10535.55	24172.49	21232.81
Office Equipment	894.09	263.07	-	1157.16	654.56	109.81	-	764.37	392.79	239.53
Furniture & Fixture	549.77	77.35	-	627.12	272.65	58.98	-	331.63	295.50	277.13
Computer	540.03	229.22	167.57	601.68	309.99	114.28	159.19	265.09	336.59	230.03
Vehicle	4790.02	-	-	4790.02	1900.70	440.31	-	2341.01	2449.00	2889.31
Total	**50588.91**	**6011.52**	**867.45**	**55732.98**	**14786.02**	**3208.15**	**402.64**	**17591.53**	**38141.44**	**35802.89**
INTANGIBLE ASSETS:										
Tally Software	51.60	-	-	51.60	49.02	-	-	49.02	2.58	2.58
Total	**50640.51**	**6011.52**	**867.45**	**55784.58**	**14835.04**	**3208.15**	**402.64**	**17640.55**	**38144.02**	**35805.47**
Previous Year	48515.82	3473.32	1348.64	50640.51	12691.96	2881.20	738.12	14835.04	35805.47	35823.86

RGMG & CO.
New Delhi
FRN:-006329N
Chartered Accountants

Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
11.OTHER NON CURRENT ASSETS		
(Unsecured -Considered Good (Unless Otherwise Stated)		
Security Deposit	200.96	200.96
Total	**200.96**	**200.96**
12.INVENTORIES		
Stock-in-Trade	38775.66	25778.87
Total	**38775.66**	**25778.87**
13. TRADE RECEIVABLE		
(i)Undisputed Trade Receivable-Considered Good		
-Less Than 6 Months	7148.04	14007.65
-6 Months-1Year	45.51	9.16
-1 -2 Years	-	300.86
-2 -3 Years	-	169.52
-More than 3 Years	10.00	-
(ii)Undisputed Trade Receivable-Considered Doubtful	-	-
(iii)Disputed Trade Receivable-Considered Good	-	-
(v)Disputed Trade Receivable-Considered Doubtful	113.06	-
Total	**7316.61**	**14487.19**
14. CASH AND CASH EQUIVALENTS		
Balance with Banks	286.54	11655.53
Cash on Hand	483.47	863.88
FDR with Bank	1104.03	875.51
Total	**1874.04**	**13394.92**
15.SHORT TERM LOANS AND ADVANCES		
[Unsecured-Considered Good (Unless Otherwise Stated)]		
Capital Advance (Agt P&M)	11728.53	10166.07
Other Advances	56.52	-
Total	**11785.04**	**10166.07**
16.OTHER CURRENT ASSETS		
Advance against Purchase	1487.73	2031.72
GST Input	542.12	68.42
Prepaid Insurance	58.51	48.00
Subsidy Receivable	750.00	-
Income Tax Refund	-	247.32
Total	**2838.36**	**2395.46**

RGMG & CO.
New Delhi
FRN:-006329N
Chartered Accountants

Notes on Financial Statement for the year ended 31st March, 2025

In Rs.,000

	2025	2024
17. REVENUE FROM OPERATIONS		
Sale of Products	129379.47	120315.27
Less: Sale of Fixed Assets	466.43	-
Total	**128913.04**	**120315.27**
18.OTHER INCOME		
Balance Written Back	-	1.98
Interest Income	69.45	46.83
Total	**69.45**	**48.80**
19.COST OF MATERIAL CONSUMED		
Opening Stock	22757.03	17955.63
Purchase during the Year	95843.27	82815.16
	118600.29	100770.79
Closing Stock	30929.46	22757.03
Total	**87670.83**	**78013.77**
20.CHANGE IN INVENTORIES OF STOCK-IN-TRADE		
Stock-in-Trade (at close)	7846.20	3021.84
Stock-in-Trade (at commencement)	3021.84	2585.72
Total	**-4824.36**	**-436.13**
21. EMPLOYEE BENEFIT EXPENSES		
Salaries and Wages	21592.35	19239.05
Provision for Gratuity	1569.39	-
Provision for Leave Encashment	538.58	-
Staff Welfare Expenses	144.02	107.87
Total	**23844.34**	**19346.92**
22. FINANCE COST		
Bank Charges	423.15	451.80
Bank Interest	4968.60	3950.13
Foreign Exchange Fluctuation	-494.84	-534.92
Total	**4896.91**	**3867.01**
23.DEPRECIATION AND AMORTISATION EXPENSES		
Depreciation	3208.15	2881.20
Total	**3208.15**	**2881.20**

RGMG & CO.
New Delhi
FRN:-005329N
Chartered Accountants

24.OTHER OPERATING EXPENSES

Consumable	452.48	466.47
Job Work Charges	337.60	80.87
Custom Duty	1468.76	1909.10
Freight	1948.53	1739.56
Clearing & Forwarding Expenses	720.24	863.19
Repair & Maintenance Charges	654.36	569.22
Power & Fuel	1702.69	1378.31
Communication Cost	21,980	68,480
Traveling & Conveyance Expenses	1214.68	592.54
Postage & Courier	272.71	81.31
Printing & Stationery	230.22	353.46
Professional Fee	686.15	588.58
Rent	30.80	-
Product Testing fee	-	14.00
Commission	-	1371.93
Insurance	94.25	101.39
Office Expenses	208.42	213.66
Business Promotion	790.28	1352.32
Water Expenses	3.90	13.43
Drug Licence Fee	100.50	28.00
Tender Fee	-	10.62
Fee & Subscription Fee	63.11	147.98
Discount & Rebate	193.27	824.01
GST Expenses	40.90	135.10
Website Expenses	59.73	37.17
Festival Expenses	-	63.54
ROC Fee	-	8.40
Other Overheads	.36	.10
Total	**11295.94**	**13012.73**

RGMG & CO.
New Delhi
FRN:-006329N
Chartered Accountants